HK Inno. N announced it will voluntarily discontinue the development of its COVID-19 vaccine due to the sudden change in the spread of COVID-19 in Korea.

With the marketing approval of SK Bioscience’s COVID-19 vaccine imminent, the indecisiveness among the other vaccine developers in Korea is increasing

According to industry sources on the 10th, HK Inno. N has decided to discontinue the development of its COVID-19 vaccine, ‘IN-B009’ in Korea. The company had been developing a recombinant vaccine, the same as SK Bioscience’s GBP510 or Novavax’s Nuvaxovid in terms of platforms.

The company pointed to the rapid change in the Korean COVID-19 situation as a reason for disc